期刊文献+

托伐普坦治疗慢性心力衰竭的疗效 被引量:3

Therapeutic effect of tolvaptan on chronic heart failure
下载PDF
导出
摘要 目的:探讨托伐普坦治疗慢性心力衰竭(CHF)的临床疗效。方法:选择2015年6月至2016年6月于我科住院的CHF患者102例。根据随机数字表,患者被分为呋塞米对照组(52例,在常规治疗基础上加用呋塞米)和托伐普坦组(50例,在常规治疗基础上加用托伐普坦)。观察比较两组治疗前后心输出量(CO)、心脏指数(CI)、每搏输出量(SV)及外周血管阻力(SVR),以及治疗效果。结果:与治疗前比较,两组治疗后CO、CI和SV均显著升高,而SVR显著降低(P均<0.01);与呋塞米对照组比较,托伐普坦组治疗后CO[(4.41±0.71)L/min比(4.80±0.77)L/min]、CI[(3.21±0.52)L·min^(-1)·m^(-2)比(3.62±0.78)L·min^(-1)·m^(-2)]和SV[(70.09±14.90)ml比(79.60±13.10)ml]升高更显著,SVR[(3111.30±931.85)dyne·s/cm^5比(2756.68±856.32)dyne·s/cm^5]降低更显著,P<0.05或<0.01。托伐普坦组的治疗总有效率显著高于常规治疗组(100.0%比75.0%),P=0.001。结论:应用托伐普坦治疗慢性心力衰竭,能明显改善心功能,临床疗效显著,值得推广。 Objective: To explore therapeutic effect of tolvaptan on chronic heart failure (CHF). Methods: A total of 102 CHF patients hospitalized in our hospital from Jun 2015 to Jun 2016 were selected. According to random number table, patients were divided into furosemide control group (n = 52, received furosemide based on routine treatment) and tolvaptan group (n = 50, received tolvaptan based on routine treatment). Cardiac output (CO), cardiac index (CI), stroke volume (SV), systemic vascular resistance (SVR) and therapeutic effect were observed and compared between two groups before and after treatment. Results: Compared with before treatment, there were significant rise in CO, CI and SV, and significant reduction in SVR in both groups after treatment, P〈0. 01 all; compared with furosemide control group after treatment, there were significant rise in CO [ (4. 41 ± 0.71) L/min vs. (4.80 ± 0.77) L/min], CI [(3.21 ± 0. 52) L · min^-1 · m^2 vs. (3.62± 0.78) L · min^-1 · m^2] and SV [(70. 09± 14.90) ml vs. (79. 60 ± 13.10) ml], and significant reduction in SVR [ (3111.30 ± 931.85) dyne · s/cms vs. (2756.68 ± 856. 32) dyne · s/cm5] in tolvaptan group, P〈0.05 or d0.01. Total effective'rate of tolvaptan group was significantly higher than that of routine treatment (100.0% vs. 75.0%), P = 0.001. Conclusion: Tolvaptan can significantly improve heart function in patients with chronic heart failure, its therapeutic effect is significant, so it's worth extending.
作者 张冬青 赵军 ZHANG Dong-qing ZHAO Jun(Department of Cardiology, Fourth Hospital of Jilln University, General Hospital of First Automotive Works, Changchun, Jllln, 130011, China)
出处 《心血管康复医学杂志》 CAS 2017年第3期303-305,共3页 Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词 心力衰竭 治疗结果 托伐普坦 Heart failure Treatment outcome Tolvaptan
  • 相关文献

参考文献3

二级参考文献42

  • 1Kalogeropoulos A, Georgiopoulou V, Kritchevsky SB, et al. Epidemiology of incident heart failure in a contemporary elderly cohort the health, aging, and body composition study[J]. Arch Int Med, 2009, 169 (7): 708 -715.
  • 2Rusinaru D, Buiciuc O, Leborgne L, et al. Relation of serum sodium level to long-term outcome after a first hospitalization for heart failure with preserved ejection fraction [J]. Am J Cardiol, 2009, 103 (3) : 405-410.
  • 3Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure an analysis from the OPTMIZE-HF registry F-J]. Eur Heart J, 2007, 28 (8); 980-988.
  • 4Nodari S, Jao GT, Chiong JR. Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients [J]. Int Nephrol Renovasc Dis, 2010, 3 (1): 51-60.
  • 5Rector TS, Francis OS, C0hn JN. Patient: s self-assessment of their congestive heart failure. Part 1: Patient perceived dysfunction and its poor correlation with maximal exercisetests [J]. Heart Failure, 1987, 3 (oct/nov): 192-196.
  • 6Rector TS, Kubo SH, Cohn JN. Patient' s sel:assessment of their congestive heart failure. Part 2: Content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire [J]. Heart Failure 1987, 3 (Oct/Nov): 198-207.
  • 7Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia [J]. N Engl J Med, 2006, 355 (20): 2099- 2112.
  • 8BerlT, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia [J]. J Am SocNephrol, 2010, 21 (4): 705-712.
  • 9Matsuzaki M, Hori M, Izumi T, et al. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase HI, randomized, double-blind, placebo-controlled study (QUEST study) [J]. Cariovasc Drugs Ther, 2011, 25 (suppl 1) : S33-45.
  • 10Hori M. Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure [J]. Future Cardiol, 2013, 9 (2): 163-176.

共引文献54

同被引文献29

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部